News | June 21, 2025
Biocon concludes a Rs 4,500 crore equity fundraise through QIP
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
25 women students to receive internship, training, and mentorship in Life Sciences segment
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
